Zafgen Inc. (NASDAQ:ZFGN) dropped 4.7% on Tuesday . The company traded as low as $3.02 and last traded at $3.02, with a volume of 248,574 shares trading hands. The stock had previously closed at $3.17.

ZFGN has been the topic of a number of recent analyst reports. FBR & Co reaffirmed a “buy” rating and set a $20.00 price target on shares of Zafgen in a report on Monday, April 4th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $19.00 price target on shares of Zafgen in a report on Tuesday, April 5th. Leerink Swann reaffirmed a “hold” rating and set a $6.00 price target on shares of Zafgen in a report on Monday, April 11th. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a report on Thursday, May 12th. Finally, Cowen and Company cut Zafgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 20th. Six analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Zafgen has an average rating of “Hold” and a consensus price target of $9.22.

The company’s 50-day moving average price is $5.44 and its 200-day moving average price is $6.38. The company’s market cap is $83.73 million.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.09. During the same quarter in the prior year, the company posted ($0.53) EPS. Equities research analysts expect that Zafgen Inc. will post ($2.62) EPS for the current fiscal year.

In other Zafgen news, Director Frances K. Heller bought 10,000 shares of the stock in a transaction that occurred on Friday, July 22nd. The shares were acquired at an average price of $2.99 per share, with a total value of $29,900.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $29,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Patricia L. Allen bought 16,000 shares of the stock in a transaction that occurred on Tuesday, July 26th. The stock was acquired at an average cost of $3.12 per share, for a total transaction of $49,920.00. The disclosure for this purchase can be found here.

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.